An observational study in Hepatocellular Cancer, sponsored by Target PharmaSolutions, Inc.. Active, not recruiting at 71 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-17.
Sponsored by Target PharmaSolutions, Inc. · Observational
TARGET-HCC is a longitudinal, observational study of patients being managed for HCC in usual clinical practice. TARGET-HCC will create a research registry of participants with HCC within academic and community real-world practices in order to assess the safety and effectiveness of the entire spectrum of current and future therapies across diverse populations.
1,391 studies on the registry are indexed under Liver Neoplasms; 345 are open to participants now.
This study's planned enrollment of 10,000 is above the median of 200 across 350 observational studies indexed under Liver Neoplasms.
Browse Liver Neoplasms studies →Target PharmaSolutions, Inc. is the lead sponsor of 16 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult patients being managed for HCC
Exclusion Criteria:
1. Inability to provide written informed consent
Establish a longitudinal observational cohort to understand the natural history and management of HCC, including the safety and outcomes of HCC treatment interventions utilized in usual clinical practice
Time frame: Up to 15 years
Evaluate the impact of HCC treatment interventions and concomitant medications on comorbid conditions and liver function
Time frame: Up to 15 years
Evaluate patient-reported outcomes measures during the natural course of HCC and management with HRQoL questionnaires
Time frame: Up to 15 years
Establish a Biorepository Specimen Bank (BSB)
Time frame: Up to 15 years
Plan to share: No
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Target PharmaSolutions, Inc.